The nanoparticles included in the Skycovion contain elements of the Spike protein, which is naturally found on the surface of the Covid Sars-Cov-2 virus and allows it to penetrate the cells of the body.
Article written by
Published
Update
Reading time : 1 min.
One of the new avenues in the fight against the pandemic. The European Medicines Agency (EMA) has started studying a new vaccine against Covid-19, developed by the German laboratory SK Chemicals and based on nanoparticles, in a press release (in English) posted Thursday, August 18.
According to the agency, the Skycovion vaccine includes nanoparticles containing elements of the Spike protein. This protein, which is on the surface of the Covid Sars-Cov-2 virus and allows it to enter human cells, is also the one that is generated by the body during vaccination using a vaccine with Messenger RNA, as recalled by the Ministry of Health.
The vaccine developed by SK Chemicals also contains an adjuvant to boost the body’s immune response to the vaccine, the agency said. The EMA adds that SK Chemicals “submitted data on the ability of this new vaccine to elicit antibody production against the original strain of SARS-CoV-2″as well as on top “the safety and quality of the vaccine”.
If approved, Skycovion will be the seventh vaccine approved in the European Union. Others are already being reviewed by the EMA in anticipation of a possible resurgence of the pandemic in the fall, such as a version of the Moderna vaccine adapted to the Omicron variant. For the moment, the European Union has authorized the use of vaccines developed by AstraZeneca, Janssen, BioNTech-Pfizer, Moderna, Novavax and Valneva, the latter having since suspended production.